RxDoctor Payments Data

Pragnan Kancharla

Internal Medicine · Pittsburgh, PANPI 1730612896

Payments from drug & device makers

$1,602in general payments, 2019–2025

Across 21 payments — averaging $76.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$394
  • E.r. Squibb & Sons, L.L.C.$217
  • AstraZeneca$124
  • Lilly USA, LLC$122
  • Bristol Myers Squibb$122
  • Incyte Corporation$106
  • plus $517 from 7 others

What the payments were for

  • Food & beverage$1,52495%
  • Education$785%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,602 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$2,549,585
Medicare patients
476
Services billed
88,058

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abiraterone Acetate46$238,393
RevlimidLenalidomide17$227,654
BrukinsaZanubrutinib15$223,455
EliquisApixaban26$26,071
XareltoRivaroxaban13$14,809
Oxycodone Hcl56$768
Prochlorperazine Maleate76$765
Ondansetron Hcl73$689
Lidocaine-PrilocaineLidocaine/Prilocaine58$670
Dexamethasone89$477
Hydroxyurea14$420
Acyclovir15$197
Prednisone58$185
Levothyroxine Sodium30$180
Warfarin Sodium12$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$122$227,65417 claims
Johnson & JohnsonXarelto$394$14,80913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →